PDF(Pubmed)
Abstract：
UNASSIGNED: In 2019, it was estimated that approximately 1.4 million adults in the United Kingdom purchased illicit cannabis to self-treat chronic physical and mental health conditions. This analysis was conducted following the rescheduling of cannabis-based medicinal products (CBMPs) in the United Kingdom but before the first specialist clinics had started treating patients.
UNASSIGNED: The aim of this study was to assess the prevalence of illicit cannabis consumption to treat a medically diagnosed condition following the introduction of specialist clinics that could prescribe legal CBMPs in the United Kingdom.
UNASSIGNED: Adults older than 18 years in the United Kingdom were invited to participate in a cross-sectional survey through YouGov between September 22 and 29, 2022. A series of questions were asked about respondents\' medical diagnoses, illicit cannabis use, the cost of purchasing illicit cannabis per month, and basic demographics. The responding sample was weighted to generate a sample representative of the adult population of the United Kingdom. Modeling of population size was conducted based on an adult (18 years or older) population of 53,369,083 according to 2021 national census data.
UNASSIGNED: There were 10,965 respondents to the questionnaire, to which weighting was applied. A total of 5700 (51.98%) respondents indicated that they were affected by a chronic health condition. The most reported condition was anxiety (n=1588, 14.48%). Of those enduring health conditions, 364 (6.38%) purchased illicit cannabis to self-treat health conditions. Based on survey responses, it was modeled that 1,770,627 (95% CI 1,073,791-2,467,001) individuals consume illicit cannabis for health conditions across the United Kingdom. In the multivariable logistic regression, the following were associated with an increased likelihood of reporting illicit cannabis use for health reasons-chronic pain, fibromyalgia, posttraumatic stress disorder, multiple sclerosis, other mental health disorders, male sex, younger age, living in London, being unemployed or not working for other reasons, and working part-time (P<.05).
UNASSIGNED: This study highlights the scale of illicit cannabis use for health reasons in the United Kingdom and the potential barriers to accessing legally prescribed CBMPs. This is an important step in developing harm reduction policies to transition these individuals, where appropriate, to CBMPs. Such policies are particularly important considering the potential risks from harmful contaminants of illicit cannabis and self-treating a medical condition without clinical oversight. Moreover, it emphasizes the need for further funding of randomized controlled trials and the use of novel methodologies to determine the efficacy of CBMPs and their use in common chronic conditions.
UNASSIGNED: The aim of this study was to assess the prevalence of illicit cannabis consumption to treat a medically diagnosed condition following the introduction of specialist clinics that could prescribe legal CBMPs in the United Kingdom.
UNASSIGNED: Adults older than 18 years in the United Kingdom were invited to participate in a cross-sectional survey through YouGov between September 22 and 29, 2022. A series of questions were asked about respondents\' medical diagnoses, illicit cannabis use, the cost of purchasing illicit cannabis per month, and basic demographics. The responding sample was weighted to generate a sample representative of the adult population of the United Kingdom. Modeling of population size was conducted based on an adult (18 years or older) population of 53,369,083 according to 2021 national census data.
UNASSIGNED: There were 10,965 respondents to the questionnaire, to which weighting was applied. A total of 5700 (51.98%) respondents indicated that they were affected by a chronic health condition. The most reported condition was anxiety (n=1588, 14.48%). Of those enduring health conditions, 364 (6.38%) purchased illicit cannabis to self-treat health conditions. Based on survey responses, it was modeled that 1,770,627 (95% CI 1,073,791-2,467,001) individuals consume illicit cannabis for health conditions across the United Kingdom. In the multivariable logistic regression, the following were associated with an increased likelihood of reporting illicit cannabis use for health reasons-chronic pain, fibromyalgia, posttraumatic stress disorder, multiple sclerosis, other mental health disorders, male sex, younger age, living in London, being unemployed or not working for other reasons, and working part-time (P<.05).
UNASSIGNED: This study highlights the scale of illicit cannabis use for health reasons in the United Kingdom and the potential barriers to accessing legally prescribed CBMPs. This is an important step in developing harm reduction policies to transition these individuals, where appropriate, to CBMPs. Such policies are particularly important considering the potential risks from harmful contaminants of illicit cannabis and self-treating a medical condition without clinical oversight. Moreover, it emphasizes the need for further funding of randomized controlled trials and the use of novel methodologies to determine the efficacy of CBMPs and their use in common chronic conditions.
摘要：
■在2019年，据估计，英国约有140万成年人购买了非法大麻，以自我治疗慢性身心健康状况。这项分析是在英国重新安排大麻基药品（CBMP）之后进行的，但在第一批专科诊所开始治疗患者之前。
■这项研究的目的是评估非法大麻消费的患病率，以治疗在英国引入可以规定合法CBMP的专科诊所后的医学诊断疾病。
■在2022年9月22日至29日期间，英国18岁以上的成年人被邀请通过YouGov参加横断面调查。关于受访者的医疗诊断，非法使用大麻,每月购买非法大麻的成本，和基本人口统计学。对响应样本进行加权以产生代表英国成年人口的样本。根据2021年全国人口普查数据，根据53,369,083的成年（18岁或以上）人口进行了人口规模建模。
■问卷有10,965名受访者，对其应用了权重。共有5700名（51.98％）受访者表示他们受到慢性健康状况的影响。报告最多的情况是焦虑（n=1588，14.48％）。在那些持久的健康状况中，364人(6.38%)购买非法大麻以自我治疗健康状况。根据调查答复，据模拟显示,英国有1,770,627人(95%CI1,073,791-2,467,001)出于健康状况而消费非法大麻.在多变量逻辑回归中，以下与出于健康原因报告非法使用大麻的可能性增加有关-慢性疼痛，纤维肌痛,创伤后应激障碍,多发性硬化症,其他精神健康障碍，男性,年龄较小,住在伦敦,失业或因其他原因不工作，和兼职工作（P<0.05）。
■这项研究强调了英国出于健康原因非法使用大麻的规模以及获取合法规定的CBMP的潜在障碍。这是制定减少伤害政策以使这些人过渡的重要一步，在适当的情况下，CBMP。考虑到非法大麻有害污染物的潜在风险以及在没有临床监督的情况下自我治疗医疗状况，这些政策尤为重要。此外，它强调需要进一步资助随机对照试验,并使用新的方法来确定CBMP的疗效及其在常见慢性疾病中的应用.
■这项研究的目的是评估非法大麻消费的患病率，以治疗在英国引入可以规定合法CBMP的专科诊所后的医学诊断疾病。
■在2022年9月22日至29日期间，英国18岁以上的成年人被邀请通过YouGov参加横断面调查。关于受访者的医疗诊断，非法使用大麻,每月购买非法大麻的成本，和基本人口统计学。对响应样本进行加权以产生代表英国成年人口的样本。根据2021年全国人口普查数据，根据53,369,083的成年（18岁或以上）人口进行了人口规模建模。
■问卷有10,965名受访者，对其应用了权重。共有5700名（51.98％）受访者表示他们受到慢性健康状况的影响。报告最多的情况是焦虑（n=1588，14.48％）。在那些持久的健康状况中，364人(6.38%)购买非法大麻以自我治疗健康状况。根据调查答复，据模拟显示,英国有1,770,627人(95%CI1,073,791-2,467,001)出于健康状况而消费非法大麻.在多变量逻辑回归中，以下与出于健康原因报告非法使用大麻的可能性增加有关-慢性疼痛，纤维肌痛,创伤后应激障碍,多发性硬化症,其他精神健康障碍，男性,年龄较小,住在伦敦,失业或因其他原因不工作，和兼职工作（P<0.05）。
■这项研究强调了英国出于健康原因非法使用大麻的规模以及获取合法规定的CBMP的潜在障碍。这是制定减少伤害政策以使这些人过渡的重要一步，在适当的情况下，CBMP。考虑到非法大麻有害污染物的潜在风险以及在没有临床监督的情况下自我治疗医疗状况，这些政策尤为重要。此外，它强调需要进一步资助随机对照试验,并使用新的方法来确定CBMP的疗效及其在常见慢性疾病中的应用.
